BeiGene, Ltd. (NASDAQ:BGNE) Given Overweight Rating at Morgan Stanley

BeiGene, Ltd. (NASDAQ:BGNE)‘s stock had its “overweight” rating reiterated by equities research analysts at Morgan Stanley in a report released on Monday. They presently have a $83.00 price objective on the stock. Morgan Stanley’s price objective would suggest a potential upside of 18.27% from the company’s previous close.

Other equities analysts also recently issued research reports about the company. Maxim Group raised their price target on BeiGene from $57.00 to $73.00 and gave the stock a “buy” rating in a research report on Friday. Zacks Investment Research downgraded BeiGene from a “hold” rating to a “sell” rating in a research report on Monday, March 27th. Robert W. Baird lifted their price objective on BeiGene from $44.00 to $58.00 and gave the company an “outperform” rating in a research report on Thursday. Finally, William Blair reaffirmed an “outperform” rating on shares of BeiGene in a research report on Thursday, June 1st. One analyst has rated the stock with a sell rating and five have given a buy rating to the company. BeiGene presently has a consensus rating of “Buy” and an average target price of $62.50.

Shares of BeiGene (NASDAQ:BGNE) traded up 2.757% during mid-day trading on Monday, reaching $72.115. The company’s stock had a trading volume of 75,602 shares. The company’s 50-day moving average is $40.06 and its 200 day moving average is $37.01. The firm’s market capitalization is $2.86 billion. BeiGene has a 1-year low of $24.53 and a 1-year high of $72.24.

WARNING: “BeiGene, Ltd. (NASDAQ:BGNE) Given Overweight Rating at Morgan Stanley” was originally reported by WKRB News and is owned by of WKRB News. If you are viewing this piece on another site, it was copied illegally and republished in violation of US & international copyright & trademark law. The correct version of this piece can be accessed at https://www.wkrb13.com/markets/2285379/beigene-ltd-nasdaqbgne-given-overweight-rating-at-morgan-stanley.html.

In other news, Director Xiaodong Wang sold 5,539 shares of BeiGene stock in a transaction on Friday, June 2nd. The stock was sold at an average price of $40.00, for a total value of $221,560.00. Following the completion of the sale, the director now owns 55,000 shares of the company’s stock, valued at $2,200,000. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO John Oyler sold 98,500 shares of BeiGene stock in a transaction on Friday, June 23rd. The shares were sold at an average price of $44.16, for a total value of $4,349,760.00. Following the completion of the sale, the chief executive officer now directly owns 88,535 shares of the company’s stock, valued at approximately $3,909,705.60. The disclosure for this sale can be found here. In the last ninety days, insiders sold 189,649 shares of company stock valued at $8,197,529. Company insiders own 24.20% of the company’s stock.

Several large investors have recently made changes to their positions in the stock. Guggenheim Capital LLC acquired a new stake in shares of BeiGene during the fourth quarter worth approximately $670,000. Norges Bank acquired a new stake in shares of BeiGene during the fourth quarter worth approximately $607,000. Vident Investment Advisory LLC increased its stake in shares of BeiGene by 9.7% in the fourth quarter. Vident Investment Advisory LLC now owns 24,958 shares of the company’s stock worth $758,000 after buying an additional 2,207 shares in the last quarter. Candriam Luxembourg S.C.A. acquired a new stake in shares of BeiGene during the first quarter worth approximately $4,210,000. Finally, ProShare Advisors LLC increased its stake in shares of BeiGene by 42.0% in the first quarter. ProShare Advisors LLC now owns 9,872 shares of the company’s stock worth $361,000 after buying an additional 2,918 shares in the last quarter. 55.69% of the stock is owned by institutional investors and hedge funds.

About BeiGene

BeiGene, Ltd. is a clinical-stage biopharmaceutical company. The Company is focused in the discovery and development of molecularly targeted and immuno-oncology drugs for the treatment of cancer. The Company had used its cancer biology platform to develop four clinical-stage drug candidates, such as BGB-3111, BGB-A317, BGB-290 and BGB-283, as of December 31, 2016.

Analyst Recommendations for BeiGene (NASDAQ:BGNE)

This story was originally published by WKRB News (https://www.wkrb13.com) and is the sole property of WKRB News. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://www.wkrb13.com/markets/2285379/beigene-ltd-nasdaqbgne-given-overweight-rating-at-morgan-stanley.html

Receive News & Ratings for BeiGene Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BeiGene Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.

 


Leave a Reply

 
© 2006-2017 WKRB News.